ICICI Direct's research report on Suven Pharmaceuticals
In accordance with Suven Life Sciences (SLS) management’s endeavour to split its innovation and CRAMs businesses, the company had announced a demerger of its CRAMS business in January, 2020 to be held by the demerged entity, Suven Pharma (SPL), while SLS will continue to hold the discovery research segment and IPs. Subsequently, SPL shares got listed on Indian bourses on March 9, 2020.
Outlook
We have a BUY rating on the stock with a target price of Rs 690 based on 20x on FY22 EPS of Rs 34.4.
Suven Pharmaceuticals 24062020-icici
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
